ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world, and its prevalence is increasing alongside obesity. In United States, NAFLD is already the second leading cause of liver transplantation. The spectrum of the disease ranges from simple steato...
ABSTRACT BACKGROUND: The vitamin B12 absorption can be affected in patients with nonalcoholic fatty liver disease (NAFLD), and low serum vitamin B12 levels has been related to the high homocysteine (HCY) levels and to the degree of NAFLD. OBJECTIVE: To carry out a systematic review and metanalysis of...
SUMMARY OBJECTIVE: Non-alcoholic fatty liver disease, which is characterized by lipid being deposited into hepatocytes, affects nearly one in three adults globally. Inflammatory markers were suggested to be related with hepatic steatosis. Uric acid to HDL cholesterol ratio is proposed as a novel inflamm...
Introducción: La enfermedad hepática grasa no alcohólica se caracteriza por un aumento de la acumulación de lípidos (triglicéridos) de forma macrovesicular, en más de 5 % de los hepatocitos, asociado o no a inflamación y/o fibrosis hepática. Objetivo: Caracterizar a pacientes con enfermedad he...
Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of hepatic pathologies ranging from simple steatosis (SS) to hepatocellular carcinoma. Intestinal microbiota (IM) is composed of trillions of microorganisms existing in the gut. It has 150 times more genes than the host. Changes in the...
ABSTRACT As a common metabolic disease, non-alcoholic fatty liver disease (NAFLD) is the most common type of liver disease in western developed countries and an important liver disease in the Asia Pacific region. At present, NAFLD lacks targeted conventional therapy and its basic treatment is the correct...
ABSTRACT Objective: We assessed plasma adiponectin and its correlation with carotid intima-media-thickness (CIMT), as a marker of atherosclerosis, and urine albumin/creatinine ratio (ACR) in patients with non-alcoholic fatty liver disease (NAFLD). Subjects and methods: The study included 100 Egyptian s...
Adiponectina/deficiencia,
Albúminas,
Enfermedades Cardiovasculares/epidemiología,
Grosor Intima-Media Carotídeo,
Creatinina,
Factores de Riesgo de Enfermedad Cardiaca,
Errores Innatos del Metabolismo/epidemiología,
Enfermedad del Hígado Graso no Alcohólico/complicaciones,
Factores de Riesgo,
Adiponectina,
Enfermedades Cardiovasculares,
Enfermedad del Hígado Graso no Alcohólico
La enfermedad por hígado graso no alcohólico (EHGNA) es una condición que incluye desde la esteatosis hepática simple y la esteatohepatitis, hasta la cirrosis hepática y eventualmente el carcinoma hepatocelular. La diabetes tipo 2 y la obesidad son los principales factores asociados a la EHGNA. Su p...
INTRODUCCIÓN: La enfermedad del hígado graso no alcohólico (EHGNA) es la forma más común de enfermedad hepática. A nivel celular se caracteriza por la acumulación de triglicéridos (TG) en forma de gotas lipídicas (GL) dando lugar a esteatosis e inflamación. Entre los factores relevantes para la...
Verbenaceae/química,
Extractos Vegetales/farmacología,
Extractos Vegetales/uso terapéutico,
Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico,
Hepatocitos/efectos de los fármacos,
Triglicéridos/análisis,
Etanol/química,
Células Hep G2/efectos de los fármacos,
Inflamación,
Técnicas de Cultivo de Célula,
Supervivencia Celular,
Reacción en Cadena de la Polimerasa,
Técnicas In Vitro,
Ácido Oléico
Chaves, Felipe Galvão Batista;
Oliveira, Glauco Ferreira de;
Ribeiro, João Paulo;
Serafim, João Victor;
Cordeiro, Luiz Felipe Medeiros;
Alvares, Matheus Alves;
Cecchi, Marcelo Trindade;
Vasquez, Murilo Cordeiro;
Souza, Thaísy Bianka Dorta de;
Rullo, Vera Esteves Vagnozzi.
ABSTRACT Objective: Evaluate the effects of probiotics use, compared with placebo, in pediatric patients with non-alcoholic fatty liver disease (NAFLD), using laboratorial and ultrasonographic parameters as outcomes. Methods: A systematic review of the literature was performed through MEDLINE and Lil...
